Feasibility of selective cardiac ventricular electroporation

Alan Sugrue¹, Vaibhav R. Vaidya¹, Christopher Livia², Deepak Padmanabhan¹, Anas Abudan¹, Ameesh Isath¹, Tyra Witt², Christopher V. DeSimone¹, Paul Stalboerger², Suraj Kapa¹, Samuel J. Asirvatham¹,³, Christopher J. McLeod¹*¹

1 Division of Heart Rhythm Services, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States of America, 2 Department of Cardiovascular Medicine and Department of Molecular Pharmacology and Experimental Therapeutics, Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, United States of America, 3 Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States of America

* mcleod.christopher@mayo.edu

Abstract

Introduction

The application of brief high voltage electrical pulses to tissue can lead to an irreversible or reversible electroporation effect in a cell-specific manner. In the management of ventricular arrhythmias, the ability to target different tissue types, specifically cardiac conduction tissue (His-Purkinje System) vs. cardiac myocardium would be advantageous. We hypothesize that pulsed electric fields (PEFs) can be applied safely to the beating heart through a catheter-based approach, and we tested whether the superficial Purkinje cells can be targeted with PEFs without injury to underlying myocardial tissue.

Methods

In an acute (n = 5) and chronic canine model (n = 6), detailed electroanatomical mapping of the left ventricle identified electrical signals from myocardial and overlying Purkinje tissue. Electroporation was effected via percutaneous catheter-based Intracardiac bipolar current delivery in the anesthetized animal. Repeat Intracardiac electrical mapping of the heart was performed at acute and chronic time points; followed by histological analysis to assess effects.

Results

PEF demonstrated an acute dose-dependent functional effect on Purkinje, with titration of pulse duration and/or voltage associated with successful acute Purkinje damage. Electrical conduction in the insulated bundle of His (n = 2) and anterior fascicle bundle (n = 2), was not affected. At 30 days repeat cardiac mapping demonstrated resilient, normal electrical conduction throughout the targeted area with no significant change in myocardial amplitude (pre 5.9 ± 1.8 mV, 30 days 5.4 ± 1.2 mV, p = 0.92). Histopathological analysis confirmed acute Purkinje fiber targeting, with chronic studies showing normal Purkinje fibers, with minimal subendocardial myocardial fibrosis.
Conclusion

PEF provides a novel, safe method for non-thermal acute modulation of the Purkinje fibers without significant injury to the underlying myocardium. Future optimization of this energy delivery is required to optimize conditions so that selective electroporation can be utilized in humans the treatment of cardiac disease.

Introduction

Electroporation, or electropermeabilization, is a phenomenon in which cell membrane permeability is increased on exposure to pulsed electric fields (PEFs). The delivery of PEFs to tissue can result in both irreversible and reversible effects. While reversible electroporation has been studied since the 1980s[1–4], the concept of irreversible electroporation is relatively new and proposed by Davlaos in 2005[5] in a landmark paper highlighting the power of electric fields to produce tissue ablation without detrimental thermal effects. While much of the initial focus on the irreversible effects of PEFs was oncological, Hong[6] and later Wittkampf[7, 8], explored cardiac applications which lead to the emergence of PEFs as a novel cardiac ablation modality[9–12].

Today, radiofrequency energy is the most common energy modality used for cardiac ablation followed by cryothermal energy. The utilization of PEFs as opposed to current approaches (radiofrequency or cryothermal energy) for targeting arrhythmonic foci is attractive as current energies for targeting cardiac tissue do not afford multifaceted cell-specific modulation, exhibiting either an all or none phenomenon (radiofrequency), or if they have reversible potential, it only provides mapping opportunities (cryomapping). Specifically, one particular limitation with current cardiac ablation energies is the inability to apply energy on or close to cardiac blood vessels. IRE has shown significant promise in this regard and led largely by the work of Maor[13–16], with all studies showing that the connective matrix of the blood vessels remained intact and the number of vascular smooth muscle in the arterial wall decreased with no evidence of aneurysm, thrombus formation or necrosis. This is a clear improvement over radiofrequency and cryothermal energy.

Recently we have seen the publication of the first in human data on atrial fibrillation PEF ablation with promising results. While there has been considerably preliminary success on atrial tissue, application on cardiac tissue has been limited. Of particular clinical value would be a means to selectively target the cardiac Purkinje system which plays a pivotal role in the genesis and maintenance of multiple different ventricular arrhythmias in both the failing and healthy heart. [17–27] In an acute ex-vivo model, PEFs delivered to the ventricular myocardium was shown to be successful in targeting Purkinje tissue[28]. In this study, PEF consistently eradicated all Purkinje potentials at voltages between 750V and 2500V and the ventricular electrogram amplitude was only minimally reduced, but not clinically significant, by ablation; 0.6 mV ± 2.3 mV (p = 0.03). Further PEF resulted in significantly reduced the window of vulnerability to ventricular fibrillation and in 4 hearts following IRE delivery, VF could not be re-induced., we sought, therefore, to further clarify the effect of PEF therapy (irreversible or reversible) on Purkinje fibers in an in-vivo model. Through dose-titrated PEF delivery, as well as electroanatomical mapping and histological analysis at both acute and chronic time points, we aimed to examine the effects of high voltage PEFs applied to the myocardium on animal survival, cardiac conduction and ventricular injury.
Methods

Animal preparation and experimental setup

The Mayo Clinic Animal Care and Use Committee approved this study involving 11 male mongrel dogs (weighing 30–40 kg). Experiments were carried out under general anesthesia with intubation and mechanical ventilation. We used ketamine (10 mg/kg), and diazepam (0.5 mg/kg) for induction and isoflurane inhalation (1–3%) for maintenance. Core body temperature was maintained at 37˚C using a heating pad placed underneath the dog. Vascular access was obtained with the modified Seldinger technique. Standard 9 French sheaths were placed percutaneously in the femoral artery, femoral veins, and the external jugular vein for catheter access to the heart. Heart rate and femoral arterial blood pressure were continuously monitored. Standard electrocardiographic leads and intracardiac electrograms filtered at 30–500 Hz were electronically recorded using a Prucka CardioLab recording system (GE Healthcare, Wauwatosa, Wisconsin). Fluoroscopy and intracardiac ultrasound (Acuson Sequoia; Siemens) were used to navigate the cardiac chambers and to guide catheter manipulation. Detailed three-dimensional electroanatomical mapping of the left ventricle via retro-aortic access was performed using the CARTO® Mapping System (Biosense Webster, Inc., Diamond Bar, CA, USA). Intracardiac mapping was performed using a Navistar® ablation catheter with 3.5 mm tip and electrode spacing of 2–5–2 mm (Biosense Webster). Heparinized saline was used to prevent intraprocedural clotting, aiming for an Activated clotting time (ACT) > 300. In the chronic studies, intravenous cefazolin (1000 mg) was given during the procedure followed by oral cepodoxime (10 mg/kg) post-procedure to prevent infection.

Electroanatomical mapping

Using the Navistar® ablation catheter, three-dimensional electro-anatomical maps were created, and mapping performed throughout the left ventricle; in addition to the annotation of the His bundle; fascicular and Purkinje signals. Fascicular potentials were labeled if a high frequency electrogram occurred before the ventricular electrogram but with a short isoelectric period intervening. Purkinje potentials (PP), which are primarily from the non-insulated portion of the conduction system and represent electrical activation of Purkinje cells/tissue, were recognized by no isoelectric period between the high-frequency PP and the ventricular electrogram. The left bundle was assumed to be a direct extension of the His potential without any atrial electrogram visible on the proximal pair of electrodes. Repeat mapping was performed at the end study utilizing the orientation of the His and coronary sinus to compare the original mapping and ablation points with the remap of the same region.

Percutaneous PEF protocol

Before delivery of the PEF, the canines received vecuronium (0.05–0.1 mg/kg) to limit muscle contraction. PEF delivery was synchronized with the QRS and delivered using the NanoKnife™ system (AngioDynamics, Queensbury, NY, USA) in a bipolar fashion between modified 8mm radiofrequency ablation catheter at sites identify with our mapping catheter. Based upon our previous ex-vivo success[28], for the chronic studies (n = 6) we delivered ten pulses in a monopolar configuration at voltages between 500-1500V at a frequency of 0.83–1 Hz with a pulse duration of 90 microseconds (μs). For the acute studies (n = 5), except the first canine, we delivered ten pulses at a frequency of 0.83–1 Hz with varying voltages (750-3000V) and a pulse duration of 20 μs. For the first acute canine, we delivered energy at the same frequency and voltage range but with a pulse duration of 90 μs, and delivered between 10–100 pulses. S1 Table shows the complete pulsed electric field parameters delivered across all acute and
chronic studies. After delivery of the PEF, if a Purkinje signal was still present (at 1 min and 5 mins), the voltage was increased and/or pulse duration changed, and repeat PEF delivered to the same location until PP eradication. The 1 min and 5 min time window was selected upon expert opinion. The persistence of PP was defined as persistence at 1 min.

The electric field was delivered between two Boston Scientific 5mm Blazer catheters (EP Technologies, Boston Scientific Corp, Natick, Massachusetts) in a bipolar configuration. The site of delivery was deliberately chosen to be nearby but not directly in contact with the PP mapped using the electroanatomical mapping catheter. The second bipolar catheter was placed in the coronary sinus and remained fixed (Fig 1). The distance between the electroporation catheter (Blazer) and the coronary sinus varied depending upon the location of the detected signal; it was, however never more than 3 cm away. The mapping catheter was not moved away from the Purkinje during electroporation delivery. After delivery of the PEF the electrogram

![Diagram of catheter locations](https://doi.org/10.1371/journal.pone.0229214.g001)

**Fig 1.** Demonstration of location of the catheters used for pulsed electric field delivery, with one catheter fixed in the coronary sinus and the other located at a Purkinje potential in the LV.
we observed for loss of the signal and recorded the voltage of the local electrogram immediately after delivery, at one and five minutes.

**Follow-up study and histologic analysis**

The survival period ranged from 19 to 36 days, with a mean of 29 days. The end procedure was performed similarly to the initial procedure although no PEF was delivered. After completing the repeat mapping, animals were sacrificed with electrical induction of ventricular fibrillation. Postmortem gross anatomic examination was performed to evaluate complications and efficacy of the PEF delivered. Histlogic samples were obtained after embedding hearts in paraffin for 1–2 weeks after the procedure. After sectioning the heart, histologic staining was performed with hematoxylin and eosin to assess tissue injury and Purkinje fiber damage. Purkinje fibers were identified by visual appearance and location.

**Statistical analysis**

Statistical analysis was performed using JMP Pro 13.0.0 software (SAS, Cary, NC). Data are expressed as mean ± standard deviation (SD) unless otherwise stated. Difference between groups was assessed using ANOVA. A p-value < 0.05 was considered significant.

**Results**

**Pulsed electric field delivery**

We delivered a total of 52 PEF therapies across five acute and six chronic canines (range 1–7 per animal) and all animals survived. The electric field magnitude delivered to the endocardium of the heart varied from 750 to 3000V, with 750 V the most commonly delivered (18/52, 35%) followed by 1125 V (10/52, 19%), and 1500 V (8/52, 15%). We mostly delivered a train of ten pulses (47/52, 90%).

**Effects on cardiac conduction tissue**

In both the acute and chronic animal models, PEF demonstrated an acute dose-dependent effect on the electrical conduction of all left ventricular Purkinje fibers. 4 PEF deliveries did not alter electrical conduction, and in these cases we had attempted PEF delivery to the His (n = 2, acute canine 4, chronic canine 3) and anterior fascicle bundle (n = 2, chronic canine 2). Fig 2 shows two typical examples of loss of Purkinje signals that we observed after PEF delivery. The His bundle was resistant to the PEF delivered with no change in its signal despite multiple deliveries (Fig 3). In the cases of the anterior fascicle, we observed loss of the signal after increasing doses of PEF but then recovery at 5 minutes (Fig 4). Table 1 displays the impact of the PEF delivered on the detected PP at different time points.

**Pulse duration**

When the train of pulses was delivered at a duration of 20 microseconds, a threshold of greater than 1800V was required to record persistent acute loss of the PP. In the cases where there was the persistence of the PP after PEF delivery, redelivery at a similar or higher voltage resulted in the loss of the PP. Specific examples from our study were the persistence of the PP at 750V which was successfully targeted with the redelivery of the PEF at 1500V; persistence at 1050V with redelivery at 1500V and then 2250V been successful; 1125V redelivered at 1500V resulting in success and lastly 1500V repeated at 1500V with subsequent success. As we have stated, there was marked resilience of the His bundle to PEF. We attempted PEF delivery to the His at 2250V; however, we were unable to alter the His signal.
When the train of pulses was delivered at 90 microseconds, a voltage greater than 1050V generally resulted in the persistent loss of the PP. Similar to our observation at a 20-microsecond pulse duration, in the cases where there was a persistence of the PP after PEF delivery, redelivery at a similar or higher voltage resulted in the acute loss of the PP. Specifically, at 750V, redelivery of the PEF at 1050V or 1125V, or an increase in the number of pulses delivered from 10 to 20 or 30 resulted in success. At 1050V and 1500V, we were unable to permanently target the His or a large anterior fascicle, respectively.

Using our previously created electroanatomical map, we returned to the exact ablation location in the chronic animals at 30 days and noted that all PP had returned.

**Effect on myocardial amplitude**

Across all animal studies, there was no statistically significant change in myocardial amplitude post-PEF delivery, over 1 minute, 5 minutes or 30 days. The mean amplitude pre-PEF delivery was $5.9 \pm 1.8 \text{ mV}$, $5.6 \pm 32.4 \text{ mV}$ 1 min post-PEF delivery, $5.4 \pm 1.2 \text{ mV}$ 5 min post-PEF and in the chronic animals $5.4 \pm 1.0 \text{ mV}$ at approximately 30 days ($p = 0.921$, Fig 5). Closer
Fig 3. Loss of small Purkinje potential, but resistance of the His to PEF.
https://doi.org/10.1371/journal.pone.0229214.g003

Fig 4. Reversible loss of a fascicular signal from PEF delivery.
https://doi.org/10.1371/journal.pone.0229214.g004
examination of the individual amplitudes at the site of delivery highlights that 1-minute post-PEF, amplitudes rarely changed by $\pm 1.5$ mV (n = 9/11, 81%), an effect that was consistent over 5 minutes (n = 8/11, 72%). In one animal (chronic animal 6) the amplitude increased after delivery but then returned to baseline. In another animal (acute animal 2), there was a decrease of 5mV from the baseline amplitude which did not recover over 5mins.

Effect on cardiac conduction

There were no significant differences detected in QRS duration after acute PEF delivery or at 30 days (Table 2). The pre-PEF QRS mean was 72.9 $\pm$ 8.4 msec, 5 mins post-PEF 76.7 $\pm$8.8 msec and at 30 days 75.5 $\pm$ 8.1 msec (p = 1.0).

Histopathological analysis

In the acute studies, the histopathological analysis confirmed acute Purkinje fiber damage in 4 of the 5 studies (Table 3, Fig 6). Acute Purkinje fiber damage was seen as hypereosinophilic fibers that had altered structure and loss of cytoplasmic detail. We observed minimal contraction band necrosis and acute endocardial hemorrhage, suggesting minimal myocardial damage. In the one animal that did experience VT, there was mild endocardial hemorrhagic and minimal contraction necrosis. Analysis of the chronic studies showed the presence of normal Purkinje fibers, with no suggestion of Purkinje damage that had been observed in the acute studies (Table 4). The PEF delivered in these animals resulted in in subendocardial fibrosis with 5 of the 6 studies showing ablation sites that were through the entire subendocardial thickness. There was minimal myocardial fibrosis observed with most of the damage occurring in the endocardium.

Complications of PEF delivery

All animals survived and tolerated PEF delivery with only one of the 11 animals experiencing a major arrhythmic complication (acute animal 2, ventricular tachycardia). One animal (chronic animal 2) experienced an idioventricular rhythm of fascicular origin after delivery of the PEF.
Fig 5. Myocardial amplitude change after Pulsed Electric Field (PEF) delivery.

Table 2. Change in QRS duration after PEF.

|                | Pre PEF | 5 mins post PEF | 30 days of PEF |
|----------------|---------|-----------------|----------------|
| Acute Animals  |         |                 |                |
| 1              | 81      | 85              | -              |
| 2              | 74      | 78              | -              |
| 3              | 69      | 65              | -              |
| 4              | 59      | 65              | -              |
| 5              | 63      | 69              | -              |
| Chronic Animals|         |                 |                |
| 1              | 84      | 86              | 80             |
| 2              | 80      | 80              | 82             |
| 3              | 82      | 84              | 82             |
| 4              | 67      | 74              | 80             |
| 5              | 76      | 89              | 84             |
| 6              | 67      | 69              | 65             |
| Mean (±SD), ms| 72.9± 8.4 | 76.7±8.8 | 7.8±6.9 |

ms- milliseconds

https://doi.org/10.1371/journal.pone.0229214.t002
Table 3. Histopathological analysis from acute animals.

| Animal | Myocardial damage | Subendocardial Ablation (average percentage) | Purkinje damage |
|--------|-------------------|---------------------------------------------|-----------------|
|        | Contraction Necrosis | Endocardial hemorrhage | No (0%) | No |
| 1      | None              | None                                      | Yes (1.0%)      | Yes |
| 2      | Minimal           | Mild                                      | Yes (5.0%)      | Yes |
| 3      | None              | Minimal                                   | Yes (1.0%)      | Yes |
| 4      | None              | Minimal                                   | Yes (1.0%)      | Yes |
| 5      | Minimal           | Minimal                                   | Yes (1.0%)      | Yes |

* A percentage of length of the entire endocardium in the section

https://doi.org/10.1371/journal.pone.0229214.1003

Fig 6. Histopathological slide showing damaged Purkinje fibers outlines in black and the purple outline demarking an area of acute hemorrhage.

https://doi.org/10.1371/journal.pone.0229214.g006
which dissipated spontaneously and did not recur. Two other animals (acute animal 1, and chronic animal 2) had a brief (<30 sec) episode of atrial fibrillation after PEF delivery which did not recur.

**Discussion**

This study highlights a novel application of PEF delivery to target cardiac Purkinje tissue, demonstrating several critical observations; 1) PEF can acutely and reversibly target Purkinje Fibers, manifesting electrically as loss of the PP and with histological analysis demonstrating acute Purkinje fiber targeting. 2) PEF Purkinje fiber targeting can be performed with minimal collateral injury to the underlying myocardium and 3) PEF can be safely delivered percutaneously to the ventricle with minimal complications.

**Selective acute targeting of cardiac tissue**

In this study, we have demonstrated that in a beating heart, delivery of PEFs can provide a cardiac cell-specific approach. We observed acutely that PEF could target the Purkinje tissue without significant myocardial damage. Specifically, delivery of a PEF resulted in acute effects on cardiac conduction, manifesting electrically as loss of the PP and with histological analysis demonstrating acute Purkinje fiber targeting. Delivery of PEF did not result in any significant myocardial damage and resulted in selective endocardial surface ablation (where Purkinje fibers are located). The ability to target the Purkinje fibers in this manner represents and highlights the potential for PEF as a novel modality which could provide irreversible cell death or enable reversible electropermeabilization, with the potential for Purkinje cell transfection. This observed approach is a welcome addition to the arena of ventricular arrhythmia management where current methods (radiofrequency or cryothermal ablation) for Purkinje arrhythmia treatment are suboptimal and not provide the potential for sparing of underlying myocardium. As we discuss below these data show that there appears to be a distinct PEF threshold difference between the Purkinje fibers and the surrounding myocardium.

The acute effects resulting in the arrest of Purkinje fiber function and the subsequent return of the PP in chronic studies we believe is indicative of the phenomenon—reversible electroporation. Reversible electroporation describes transient permeabilization of a cell whereby after application of an electric field the cell membrane ressealed, and the cell subsequently restores homeostasis. It is the basis of gene transfer into cells[29, 30], delivery of drugs into cells[31–33] and electrochemotherapy[34–36]. We postulate that the return of the Purkinje signal (Fig 4) has the potential for significant clinical implications in novel arrhythmia management. Reversible electroporation can provide a means for delivery of a vector into the Purkinje cell/fiber or

| Animal | Endocardial fibrosis | Myocardial fibrosis | Subendocardial Ablation (average percentage)* | Purkinje damage |
|--------|----------------------|---------------------|-------------------------------------------|-----------------|
| 1      | Minimal              | Minimal             | Yes (11.7%)                                | No              |
| 2      | None                 | None                | No                                         | No              |
| 3      | Minimal              | Minimal             | Yes (15.0%)                                | No              |
| 4      | Minimal              | Minimal             | Yes (24.0%)                                | No              |
| 5      | Minimal              | Minimal             | Yes (17.5%)                                | No              |
| 6      | Minimal              | Minimal             | Yes (11.7%)                                | No              |

* A percentage of length of the entire endocardium in the section

https://doi.org/10.1371/journal.pone.0229214.t004
temporarily disruption of Purkinje conduction. We postulate that this opens opportunities for the development of the vaccines for arrhythmia management in the context of all Purkinje-related arrhythmias[21, 27, 37]. Additionally this also provides a means for abrupt and temporary arrest of Purkinje conduction in the acute setting of recalcitrant arrhythmias such as VF storm.

Further validation and mechanistic elucidation of this effect should entail the integration of reporter molecules that confirm cell membrane permeability[38]. An alternative hypothesis that could explain the return of the PP at 30 days is that there was the recovery of function from either regrowth and repair of the Purkinje fiber which has been reported after irreversible electroporation of sciatic nerve fibers.[39, 40] Our histological analyses did not, however, suggest new growth/Purkinje repair.

Not only is the reversible effect of PEF important but future optimization will enable the delivery of a durable irreversible ablation effect would have substantial clinical implications in arrhythmogenesis control. As discussed in the introduction, the cardiac Purkinje system plays a critical role in the genesis and maintenance of multiple ventricular arrhythmias including VF with abolition of the Purkinje fiber function, in animal models, conferring improved tolerance/resistance towards VF.[26, 28, 41] Therefore complete ablation of these fibers would present a novel method for VF ablation. Further, focal activity generated in the subendocardial Purkinje tissue has been reported to be the primary, if not the only, trigger for torsade de pointes in experimental long QT models.[41]

**Safety of PEF cardiac delivery**

Use of PEFs in non-cardiac applications has resulted in both lethal and non-lethal cardiac arrhythmias [42–44]. To mitigate this risk, ECG synchronization during pulse delivery is a critical tool in ensuring that the energy is delivered during the absolute refractory period of the cardiac cycle. In this investigation, the delivery of electrical pulses was linked to a proprietary external R wave triggering device. Via R-wave detection and gating of delivery to coincide with this fiduciary marker, the device is triggered to deliver a pulse 50 milliseconds after each R wave[45, 46]. While delivery of PEF to atrial tissue and over the ventricular epicardial surface has been reported, this *in-vivo* investigation highlights that endocardial ventricular PEF delivery (at significant voltages) can be delivered safely with only one animal (acute animal 2) experiencing an arrhythmia. In this animal, we did notice a significant drop in myocardial voltage after PEF, and although histology did not show significant myocardial damage, it was more significant than what was observed in the other animals. One animal experienced an idioventricular rhythm of fascicular origin, this dissipated spontaneously and did not recur. Considering all published preclinical[8, 10, 47–49] and the recent first in human clinical data [50], it is reasonable to deduce that that direct cardiac IRE delivery within the ventricle or atrium (epicardial or endocardium) is reasonably safe (when timed with R wave).

**Tissue specificity and collateral damage**

Tissue selectivity with PEF presents an entirely novel, unique, and attractive element in the management of arrhythmias. The arborizing nature of the Purkinje fibers makes them difficult to effectively target and ablate with current energy modalities (radiofrequency and cryothermal energy). Furthermore, these energy modalities cannot confer cell-specific targeting of ventricular myocardium. In this study, acute targeting of the Purkinje fibers (confirmed with loss of electrical signal and histological analysis) with minimal surrounding myocardial damage advances the applicability from largely non-cardiac, gross ablation of solid tissue into a realm of precise ventricular tissue “dissection.” The resilience of the His Bundle to the PEF may
derive from the tissue selectivity of PEF, yet the penetrating segment is also encased in a collag-
igenous/fibrous sheath[51], which we hypothesize, results in altered electrical field distribution
and dispersion[52]. Although, not penetrating, and subendocardial in location, larger fascicles
also retain insulation, which also will render different electroporative susceptibility to the
underlying conducting tissue. This was seen, where at higher energies, successful eradication
of electrical conduction occurred but returned after 5 minutes. The exact threshold for defini-
tive, durable ablation of the His, Fascicle and Purkinje requires further elucidation. It has been
reported that myocardium retains a threshold of > 375 V/cm[53], but this was defined at a
pulse length of 50 microseconds and in isolated cardiac cells, not heterogeneous, beating tissue
in a blood pool—all of which will likely alter field vector and delivery[54, 55]. Extrapolation is
therefore not reliable for clinical applications from the in-vitro models and optimization for
beating ventricular myocardium is necessary following this proof-of-concept investigation
Additionally, as future studies are performed and different pulse protocols are explored, joule
heating may occur in which irreversible electroporation is the goal. To achieve an irreversible
effect higher voltages, greater pulses, or nanosecond pulse width may be required which could
potentially result in Joule heating. Joule heating may result in loss of selectivity and therefore a
tradeoff may exist between cell selective and non-selective irreversible damage. These consid-
erations aside, this preliminary study presents inviting proof-of-concept data, which demon-
strate acute differences in tissue selectivity, and whether or not increased energy delivery to
permanently ablate the Purkinje will also show such selectivity remains to be determined.

Tissue contact and the electrical field effect
Another key differentiator between currently available cardiac ablation tools and PEF catheters
is the requirement for tissue contact. Compared with thermal/radiofrequency modalities, this
fundamental tenet does not apply to PEF, and the field of effect allows for less precise delivery
for widespread targeting of tissue. There is also a potential vulnerability for specific arrhythmia
syndromes where tissue vulnerability is conferred by tissue type, and not contact, and is yet a
particularly attractive feature where the tissue of interest retain distinctly different cellular
membrane constituents.

Limitations
It is essential to understand that the effect of PEF is directly related to the electric field deliv-
ered and its distribution in tissue. Although we state the overall voltage delivered, determina-
tion of the actual electric field distribution is complex and relies on tissue conductivity which
was not feasible to calculate [56]. Moreover, the pulse length was not kept constant between
acute and chronic studies. This may limit inference of the acute damage observed in the acute
experiments into our chronic studies, however, based upon our experience over these sets of
experiments; we feel acute effects on Purkinje fiber function was consistent through the
chronic studies; additionally, we used a standard ablation catheter not designed of electropora-
tion delivery; the development of an optimized bipolar device may yield different results. The
Navistar catheter is a “blunt tool” for mapping fine electrical fascicular signals, and for detect-
ing discrete changes in myocardial voltage. More subtle electrophysiological signals would be
identified with the use of closer-spaced, smaller electrodes, and this is being employed in iter-
tative work. Additionally, the use of the Navistar catheter instead of a multielectrode catheter
may have resulted in missing subtle changes in voltages that said, histology confirmed that we
generally had preservation of the myocardium. Finally, although we did not observe any
changes in the QRS duration, we did not specifically examine for any change in Purkinje fiber
conduction with analysis of the His bundle-ventricular interval pre and post-ablation. The
functional significance of the PEF on the cardiac fascicular/Purkinje tissue and its relationship to arrhythmia syndromes such as ventricular fibrillation is an area that requires deeper study. Determination and validation of the models will be pivotal. These investigations were undertaken in the normal heart, and whether salutary effects persist across diseased myocardial substrates commonly seen in the patient prone to VT/VF remains to be determined.

**Conclusion**

PEF can be safely delivered to the endocardium of the ventricle and at our pulsing protocol we have observed a dose-dependent cell-specific effect on ventricular myocardium. Specifically with the energy we delivered, we observed a PEF effect on electrical conduction on all left ventricular Purkinje fibers with limited damage to the underlying myocardium in canine studies. Further study and electric field modification are necessary to study reversible and irreversible effects on these fibers, as well as implications for cardiac conduction, mechanical function and especially ventricular arrhythmia initiation and propagation.

**Supporting information**

S1 Table. Complete pulsed electric field parameters of the delivery across all acute and chronic studies.

(DOCX)

**Author Contributions**

Conceptualization: Alan Sugrue, Vaibhav R. Vaidya, Christopher Livia, Deepak Padmanabhan, Anas Abudan, Ameesh Isath, Tyra Witt, Christopher V. DeSimone, Paul Stalboerger, Suraj Kapa, Samuel J. Asirvatham, Christopher J. McLeod.

Data curation: Alan Sugrue, Vaibhav R. Vaidya, Christopher Livia, Deepak Padmanabhan, Anas Abudan, Ameesh Isath, Tyra Witt, Paul Stalboerger, Suraj Kapa, Christopher J. McLeod.

Formal analysis: Alan Sugrue, Vaibhav R. Vaidya, Christopher Livia, Deepak Padmanabhan, Anas Abudan, Ameesh Isath, Tyra Witt, Suraj Kapa, Samuel J. Asirvatham, Christopher J. McLeod.

Investigation: Alan Sugrue, Vaibhav R. Vaidya, Christopher Livia, Tyra Witt, Christopher V. DeSimone, Paul Stalboerger, Christopher J. McLeod.

Methodology: Alan Sugrue, Tyra Witt, Christopher V. DeSimone, Christopher J. McLeod.

Project administration: Tyra Witt, Paul Stalboerger, Christopher J. McLeod.

Resources: Paul Stalboerger.

Supervision: Christopher J. McLeod.

Writing – original draft: Alan Sugrue, Vaibhav R. Vaidya, Christopher V. DeSimone, Suraj Kapa, Samuel J. Asirvatham, Christopher J. McLeod.

Writing – review & editing: Alan Sugrue, Vaibhav R. Vaidya, Christopher Livia, Deepak Padmanabhan, Christopher V. DeSimone, Suraj Kapa, Samuel J. Asirvatham, Christopher J. McLeod.
References

1. Benz R, Zimmermann U. Pulse-length dependence of the electrical breakdown in lipid bilayer membranes. Biochimica et biophysica acta. 1980; 597:637–42. https://doi.org/10.1016/0005-2736(80)90236-9 PMID: 7378404

2. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lymphoma cells by electroporation in high electric fields. The EMBO journal. 1982; 1:841–5. PMID: 6329708

3. Glaser RW, Leikin SL, Chernomordik LV, Pastushenko VF, Sokirko AI. Reversible electrical breakdown of lipid bilayers: formation and evolution of pores. Biochimica et biophysica acta. 1988; 940:275–87. https://doi.org/10.1016/0005-2736(88)90202-7 PMID: 2453213

4. Chang DC, Reese TS. Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy. Biophysical Journal. 1990; 58:1–12. https://doi.org/10.1016/S0006-3495(90)82348-1 PMID: 2383626

5. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Annals of Biomedical Engineering. 2005; 33:223–31. https://doi.org/10.1016/s0883-7254(05)80034-4 PMID: 15771276

6. Hong J, Stewart MT, Cheek DS, Francischielli DE, Kirchhof N. Cardiac ablation via electroporation. Conference proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference. 2009; 2009:3381–4.

7. Wittkampf FH, van Driel VJ, van Wessel H, Neven KG, Gründeman PF, Vink A, et al. Myocardial lesion depth with circular electroporation ablation. Circulation: Arrhythmia and Electrophysiology. 2012;CIRCEP. 111.970079. https://doi.org/10.1161/CIRCEP.112.975888

8. Wittkampf FH, Van Driel VJ, Van Wessel H, Vink A, Hof IE, Gründeman PF, et al. Feasibility of electroporation for the creation of pulmonary vein ostial lesions. Journal of Cardiovascular Electrophysiology. 2011; 22(3):302–9. https://doi.org/10.1111/j.1540-8167.2010.01863.x PMID: 20653809

9. Sugrue A, Maor E, Ivorra A, Vaidya V, Witt C, Kapa S, et al. Irreversible electroporation for the treatment of cardiac arrhythmias. Expert review of cardiovascular therapy. 2018.

10. Witt CM, Sugrue A, Padmanabhan D, Vaidya V, Gruba S, Rohl J, et al. Intrapulmonary Vein Ablation Without Stenosis: A Novel Balloon-Based Direct Current Electroporation Approach. J Am Heart Assoc. 2018; 7(14).

11. Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. Journal of the American College of Cardiology. 2019.

12. Stewart MT, Haines DE, Verma A, Kirchhof N, Barka N, Grassl E, et al. Intracardiac pulsed field ablation: proof of feasibility in a chronic porcine model. Heart rhythm. 2019; 16(5):754–64. https://doi.org/10.1016/j.hrthm.2018.10.030 PMID: 30385383

13. Maor E, Ivorra A, Mitchell JJ, Rubinsky B. Vascular smooth muscle cells ablation with endovascular nonthermal irreversible electroporation. Journal of Vascular and Interventional Radiology. 2010; 21(11):1706–15. https://doi.org/10.1016/j.jvir.2010.06.024 PMID: 20933436

14. Maor E, Ivorra A, Rubinsky B. Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation. PLoS one. 2009; 4(3):e4757. https://doi.org/10.1371/journal.pone.0004757 PMID: 19270746

15. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technology in cancer research & treatment. 2007; 6(4):307–12.

16. Maor E, Ivorra A, Leor J, Rubinsky B. Irreversible electroporation attenuates neointimal formation after angioplasty. IEEE Transactions on Biomedical Engineering. 2008; 55(9):2268–74. https://doi.org/10.1109/TBME.2008.923909 PMID: 18713696

17. Boydgen PA, Dun W, Robinson RB. Cardiac Purkinje fibers and arrhythmias; The GK Moe Award Lecture 2015. Heart rhythm. 2016; 13(5):1172–81. https://doi.org/10.1016/j.hrthm.2016.01.011 PMID: 26775142

18. Lopera G, Stevenson WG, Soejima K, Maisel WH, Koplan B, Sapp J, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. Journal of Cardiovascular Electrophysiology. 2004; 15(1):52–8. https://doi.org/10.1046/j.1540-8167.2004.03189.x PMID: 15028072

19. Huang J, Dodsall DJ, Cheng K-A, Li L, Rogers JM, Ideker RE. The importance of Purkinje activation in long duration ventricular fibrillation. Journal of the American Heart Association. 2014; 3(1):e000495. https://doi.org/10.1161/JAHA.113.000495 PMID: 24384738

20. Nogami A, Sugiyasu A, Kubota S, Kato K. Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system. Heart Rhythm. 2005; 2(6):646–9. https://doi.org/10.1016/j.hrthm.2005.02.006 PMID: 15922276
21. Sung RK, Boyden PA, Scheinman M. Cellular Physiology and Clinical Manifestations of Fascicular Arrhythmias in Normal Hearts. JACC Clinical electrophysiology. 2017; 3(12):1343–55. https://doi.org/10.1016/j.jacep.2017.07.011 PMID: 29759663

22. Lang D, Holzem K, Kang C, Xiao M, Hwang HJ, Ewald GA, et al. Arrhythmogenic remodeling of beta2 versus beta1 adrenergic signaling in the human failing heart. Circulation Arrhythmia and electrophysiology. 2015; 8(2):409–19. https://doi.org/10.1161/CIRCEP.114.002065 PMID: 25673629

23. Walton RD, Martinez ME, Bishop MJ, Hocini M, Haissaguerre M, Plank G, et al. Influence of the Purkinje-muscle junction on transmural repolarization heterogeneity. Cardiovascular research. 2014; 103(4):629–40. https://doi.org/10.1093/cvr/cvu165 PMID: 24997066

24. Han W, Zhang L, Schram G, Nattel S. Properties of potassium currents in Purkinje cells of failing human hearts. American journal of physiology Heart and circulatory function. 2002; 283(6):H2495–503. https://doi.org/10.1152/ajpheart.00389.2002 PMID: 12388306

25. Han W, Chartier D, Li D, Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation. 2001; 104(17):2095–102. https://doi.org/10.1161/01. HCA.0000049549.90569.2e PMID: 11673352

26. Dosdall DJ, Tabereaux PB, Kim JJ, Walcott GP, Rogers JM, Killingsworth CR, et al. Chemical ablation of the Purkinje system causes early termination and activation rate slowing of long-duration ventricular fibrillation in dogs. American Journal of Physiology-Heart and Circulatory Physiology. 2008; 295(2):H883–H9. https://doi.org/10.1152/ajpheart.00466.2008 PMID: 18586887

27. Gianni C, Burkhardt JD, Trivedi C, Mohanty S, Natale A. The role of the Purkinje network in premature ventricular complex-triggered ventricular fibrillation. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing. 2018.

28. Livia C, Sugrue A, Witt T, Polkinghorne MD, Maor E, Kapa S, et al. Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability. Journal of the American Heart Association. 2018; 7(15):e009070. https://doi.org/10.1161/JAHA.118.009070 PMID: 30371233

29. Neumann E. Membrane electroporation and direct gene transfer. Bioelectrochemistry and Bioenergetics. 1992; 28:247–67.

30. Rosazza C, Haberl Meglic S, Zumbusch A, Rols M-P, Miklavcic D. Gene electroporation: a mechanistic perspective. Current gene therapy. 2016; 16(2):98–129. https://doi.org/10.2174/156652316666160331130040 PMID: 27029943

31. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Japanese journal of cancer research: Gann. 1987; 78(12):1319–21. PMID: 2448275

32. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electroporation of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochemical pharmacology. 1988; 37(24):4727–33. https://doi.org/10.1016/0006-2952(88)90344-9 PMID: 2462423

33. Serša G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diammine-dichloroplatinum (II) in mice. Cancer research. 1995; 55(15):3450–5. PMID: 7614485

34. Mir LM, Belehradeck M, Domenge C, Orlowski S, Poddevin B, Belehradek J Jr., et al. [Electrochemotherapy, a new antitumor treatment: first clinical trial]. Comptes rendus de l’Academie des sciences Serie III, Sciences de la vie. 1991; 313(13):613–8. PMID: 1723647

35. Marty M, Sersa G, Barbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy—An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. European Journal of Cancer Supplements. 2006; 4(11):3–13.

36. Miklavčič D, Mali B, Kos B, Heller R, Serša G. Electrochemotherapy: from the drawing board into medical practice. Biomedical engineering online. 2014; 13(1):29. https://doi.org/10.1186/1475-9255-13-29 PMID: 24621079

37. Haissaguerre M, Shah DC, Jais P, Shoda M, Kautzner J, Arentz T, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet (London, England). 2002; 359(9307):677–8.

38. Kranjc M, Markelc B, Bajf D, Čemažar M, Serša I, Blagus T, et al. In situ monitoring of electric field distribution in mouse tumor during electroporation. Radiology. 2014; 274(1):115–23. https://doi.org/10.1148/radiol.14140311 PMID: 25146467

39. Schoellnast H, Monette S, Ezel PC, Deodhar A, Maybody M, Erinjeri JP, et al. Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model. Radiology. 2011; 260(2):421–7. https://doi.org/10.1148/radiol.11103505 PMID: 21642418

40. Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PloS one. 2011; 6(4):e18831. https://doi.org/10.1371/journal.pone.0018831 PMID: 21533143
41. Ben Caref E, Boutjdir M, Himel HD, El-Sherif N. Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. Europace. 2008; 10(10):1218–23. https://doi.org/10.1093/europace/eun248 PMID: 18757866

42. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. Journal of vascular and interventional radiology: JVIR. 2011; 22(5):611–21. https://doi.org/10.1016/j.jvir.2010.12.014 PMID: 21439847

43. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2011; 13(3):168–73.

44. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. Journal of surgical oncology. 2013; 107(5):544–9. https://doi.org/10.1002/jso.23280 PMID: 23090720

45. Mali B, Gorjup V, Edhemovic I, Breccia E, Cemazar M, Sersa G, et al. Electrochemotherapy of colorectal liver metastases—an observational study of its effects on the electrocardiogram. Biomedical engineering online. 2015; 14(3):S5.

46. Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadosi R. Design of an irreversible electroporation system for clinical use. Technology in cancer research & treatment. 2007; 6(4):313–20.

47. Wojtaszczyk A, Caluori G, Pešl M, Melajova K, Stárek Z. Irreversible electroporation ablation for atrial fibrillation. Journal of cardiovascular electrophysiology. 2018; 29(4):643–51. https://doi.org/10.1111/jce.13454 PMID: 29399927

48. Wittkampf FH, van Es R, Neven K. Electroporation and its relevance for cardiac catheter ablation. JACC: Clinical Electrophysiology. 2018.

49. van Driel VJ, Neven KG, van Wessel H, Bastiaan C, Vink A, Doevendans PA, et al. Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency. Circulation: Arrhythmia and Electrophysiology. 2014;CIRCEP. 113.001111.

50. Reddy VY, Koruth J, Jais P, Petro J, Timko F, Skalsky I, et al. Ablation of Atrial Fibrillation With Pulsed Electric Fields. An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation. 2018.

51. James TN, Sherf L. Fine structure of the His bundle. Circulation. 1971; 44(1):9–28. https://doi.org/10.1161/01.cir.44.1.9 PMID: 5561420

52. Agnaral A, Zudans I, Weber EA, Olofsson J, Orwar O, Weber SG. Effect of cell size and shape on single-cell electroporation. Analytical chemistry. 2007; 79(10):3589–96. https://doi.org/10.1021/ac062049e PMID: 17444611

53. Kaminska I, Kotulska M, Stecka A, Saczko J, Drag-Zalesinska M, Wysocka T, et al. Electroporation-induced changes in normal immature rat myoblasts (H9C2). Gen Physiol Biophys. 2012; 31(1):19–25. https://doi.org/10.4149/gpb_2012_003 PMID: 22447827

54. Golberg A, Bruinsma BG, Uygun BE, Yarmush ML. Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by “electric field sinks”. Scientific reports. 2015; 5:8485. https://doi.org/10.1038/srep08485 PMID: 25684630

55. Kos B, Voigt P, Miklavcic D, Moche M. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE). Radiology and oncology. 2015; 49(3):234–41. https://doi.org/10.1515/raon-2015-0031 PMID: 26401128

56. Corovic S, Lackovic I, Sustaric P, Sustar T, Rodic T, Miklavcic D. Modeling of electric field distribution in tissues during electroporation. Biomedical engineering online. 2013; 12(1):16.